Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- Pfizer
- Study ID
- NCT01375127
- Status
- Completed
Conditions
- Kidney Transplantation
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- Tofacitinib — DRUGSubjects who previously took 15 mg BID or 30 mg BID
- Tofacitinib — DRUGSubjects who previously took 15 mg BID for 3 months then 10 mg BID, or 15 mg BID for 6 months then 10 mg BID
Study Details
This is an observational study designed to collect follow-up clinical date on subjects who were treated with tofacitinib in 2 completed Phase 2 studies who either discontinued treatment prematurely or did not elect to enroll in long-term extension studies.
Key Dates
- Start date
- Aug 31, 2011
- Status verified
- Sep 2013
- Primary completion
- Jul 31, 2012
- Completion
- Jul 31, 2012
Study Design
- Enrollment
- 83 participants (actual)
Arms
- Arm: Subjects from Study A3921009
- Arm: Subjects from Study A3921030
Primary Outcome Measure
Number of Participants With Clinical Outcome of Post Transplant Lymphoproliferative Disease (PTLD) [ Time Frame: Baseline through Month 12 ]
Locations (23)
Find similar trials in Los Angeles, CA
Related Studies
- Shingrix in Renal Transplant RecipientsPHASE3 · Recruiting · University of Colorado, Denver · Aurora, Colorado
- REgulatory T Cell Therapy to Achieve Immunosuppression REductionPHASE2 · Recruiting · Singulera Therapeutics Inc. · Phoenix, Arizona
- Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.PHASE4 · Recruiting · Mayo Clinic · Phoenix, Arizona
- Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney TransplantationPHASE2 · Recruiting · Alexion Pharmaceuticals, Inc. · Birmingham, Alabama